Open AccessTwo-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2
Author(s) -
William Hardy,
Roy M. Gulick,
Howard Mayer,
Gerd Fätkenheuer,
Mark Nelson,
Jayvant Heera,
Natasa Rajicic,
James Goodrich
Publication year - 2010
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0b013e3181ee3d82
Subject(s) - maraviroc , ccr5 receptor antagonist , medicine , placebo , regimen , viral load , adverse effect , randomized controlled trial , human immunodeficiency virus (hiv) , immunology , chemokine , receptor , alternative medicine , pathology , chemokine receptor
Maraviroc, the first approved CCR5 antagonist, demonstrated 48-week safety and virologic efficacy in CCR5-tropic HIV-infected, treatment-experienced patients; however, critical longer-term safety and durability of responses are unknown.